• Citrix Application Performance Management
• Cloud-based Contact Center
• Cloud Communications
• Cloud Hosting
• Cloud Management
• Data Center Power
• Hadoop
• Network Diagramming
• Out-of-Band Management
• Power Protection
• SaaS Licensing
• SIM Server
• SMARTnet
• Software Licensing
• Software Monetization
• Toll Free Number
• Wi-Fi Network
• WLAN

[January 16, 2013] Transgene Announces its Financial Calendar for 2013 STRASBOURG, France --(Business Wire)-- Regulatory News: Transgene SA (Euronext Paris: FR0005175080) (Paris:TNG) today announces the following financial reporting dates for 2013:
March 22, 2013:	�	2012 Annual Results and Strategic Update
		�
April 22, 2013		Q1 Financial Report
		�
June 19, 2013:		Annual Shareholders' Meeting
		�
September 12, 2013:		Half-Year Financial Report
		�
October 21, 2013:		Q3 Financial Report

About Transgene:

Transgene, a member of the Institut M�rieux Group, is a publicly traded French biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. Transgene has four compounds in phase 2 clinical development: TG4010 and JX594/TG6006 having already completed initial phase 2 trials, TG4001 and TG4040. Transgene has concluded strategic agreements for the development of two of its immunotherapy products: an option agreement with Novartis for the development of TG4010 to treat various cancers and an in-licensing agreement with US-based Jennerex, Inc. to develop and market JX594/TG6006, an oncolytic virus. Transgene has bio-manufacturing capacities for viral-based products. Additional information about Transgene is available at www.transgene.fr.

Soci�t� anonyme au capital de 72.523.405 � - R.C. Strasbourg B 317 540 581

400 boulevard Gonthier d'Andernach - Parc d'Innovation - CS80166 - 67405 ILLKIRCH GRAFFENSTADEN CEDEX (France)

T�l�: + 33 (0)3 88 27 91 00

[ InfoTech Spotlight's Homepage ]

infoTECH Headlines

infoTECH Whitepapers

What is Information Tehnology